• Gregory J Fermann, Petra M G Erkens, Martin H Prins, Philip S Wells, Ákos F Pap, and Anthonie W A Lensing.
• Department of Emergency Medicine, University of Cincinnati, Cincinnati, OH.
• Acad Emerg Med. 2015 Mar 1;22(3):299-307.

ObjectivesThe objective was to assess adverse outcomes in relation to the simplified Pulmonary Embolism Severity Index (PESI) score in patients treated with rivaroxaban or standard therapy in the phase III EINSTEIN PE study and to evaluate the utility of the simplified PESI score to identify low-risk pulmonary embolism (PE) patients.MethodsA post hoc analysis of EINSTEIN PE data was performed to assess the efficacy and safety of rivaroxaban in patients with a range of simplified PESI scores. Recurrent venous thromboembolism, fatal PE, all-cause mortality, and major bleeding were stratified by simplified PESI scores of 0, 1, or ≥2 and according to treatment period at 7, 14, 30, and 90 days and at the end of the full intended treatment period.ResultsSimplified PESI scores could be calculated in 4,831 of the 4,832 randomized patients; of those, 53.6, 36.7, and 9.7% had PESI scores of 0, 1, and ≥2, respectively. Among patients with simplified PESI scores of 0 or 1, fatal PE, all-cause mortality, and other adverse outcomes were uncommon within the first 7, 14, and 30 days. Patients with simplified PESI scores of ≥2 had more frequent adverse outcomes. Major bleeding was lower in the rivaroxaban group, particularly in those with simplified PESI scores of 1 or ≥2.ConclusionsThe findings support using risk stratification with the simplified PESI score to identify low-risk patients with PE.© 2015 The Authors. Academic Emergency Medicine published by Wiley Periodicals, Inc. on behalf of Society for Acadamic Emergency Medicine.

45 keywords...

hide…